Royalty Pharma plc SEC filings RPRX
Royalty Pharma plc has 636 filings in SEC EDGAR's recent list, going back to Feb 13, 2020. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 13F-NT | Filing | Aug 14, 2026 | Jun 30, 2026 |
| 13F-NT | Filing | May 14, 2026 | Mar 31, 2026 |
| 13F-NT | Filing | Apr 1, 2026 | Dec 31, 2025 |
| POSASR | Filing | Sep 2, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2025 | — |
| 425 | Form 425 | Jan 15, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2024 | — |
| CORRESP | Letter to the SEC | Jan 24, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 27, 2023 | — |
| CORRESP | Letter to the SEC | Sep 19, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2023 | — |
| CORRESP | Letter to the SEC | Jul 13, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 28, 2023 | — |
| APP ORDR | Filing | Nov 22, 2022 | — |
| APP NTC | Filing | Nov 1, 2022 | — |
| 40-APP | Form 40-app | Sep 20, 2022 | — |
| EFFECT | Filing | Jul 7, 2021 | — |
| CORRESP | Letter to the SEC | Jul 1, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 25, 2021 | — |
| EFFECT | Filing | Oct 15, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2020 | — |
| DRS | Filing | Sep 29, 2020 | — |
| SEC STAFF LETTER | Filing | Jun 15, 2020 | — |
| EFFECT | Filing | Jun 15, 2020 | — |
| CERT | Filing | Jun 15, 2020 | — |
| 8-A12B | Filing | Jun 15, 2020 | — |
| CORRESP | Letter to the SEC | Jun 11, 2020 | — |
| CORRESP | Letter to the SEC | Jun 11, 2020 | — |
| CORRESP | Letter to the SEC | Jun 11, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2020 | — |
| SEC STAFF LETTER | Filing | Jun 5, 2020 | — |
| DRS/A | Filing | May 19, 2020 | — |
| DRS/A | Filing | May 18, 2020 | — |
| DRSLTR | Filing | May 15, 2020 | — |
| UPLOAD | Letter from the SEC | May 8, 2020 | — |
| DRS/A | Filing | Apr 23, 2020 | — |
| DRSLTR | Filing | Apr 22, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2020 | — |
| DRS/A | Filing | Mar 27, 2020 | — |
| DRSLTR | Filing | Mar 26, 2020 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2020 | — |
| DRS | Filing | Feb 13, 2020 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RPRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1802768
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.